Chemical company Chemours was spun off from DuPont in 2015. Image source: Getty Images.

What happened

Shares of chemical company Chemours (NYSE:CC) had an amazing November, rising 46.8% on the heels of a great Q3 earnings report. This was on top of already-huge gains in August after positive Q2 earnings. As of the end of November, the stock had climbed a mind-boggling 351%, handily crushing the S&P 500 and chemical peers such as DuPont (NYSE:DD):

CC Chart

CC data by YCharts

So what

Obviously, these are extraordinary numbers, but a little bit of context is needed. Chemours' stock may be having an awesome 2016, but 2015 was a different story for the company. When it was spun off from DuPont in July 2015, its former parent loaded it up with massive legal and environmental liabilities as well as $4 billion in net debt. So it's no surprise that the stock promptly sank, losing more than two-thirds of its value by the end of the year. 

So even with the stock's fantastic gains so far in 2016, investors who found themselves owning the stock after the spinoff hadn't benefited. But with November's performance, they are now handily beating the market:

CC Chart

CC data by YCharts

Chemours has made progress paying off its debt and expects its total debt load by year's end to be down to about three times EBITDA, compared with five times EBITDA at the time of the spinoff. The company's titanium dioxide business, which had been in trouble thanks to lower sales and falling global prices, is finally recovering, with earnings up 80% YOY. In short, things are looking a lot better for Chemours than they were a year ago.

Now what

Despite improving market conditions, you should still be cautious about buying Chemours stock, because those legal and environmental liabilities haven't gone away. In fact, in the case of one chemical, PFOA, the litigation is just beginning, with 40 trials scheduled for next year alone. The first two PFOA trials resulted in a combined $7.2 million in judgments against DuPont, which are currently being appealed.

Chemours has agreed to indemnify DuPont for any damages resulting from PFOA litigation. If Chemours is held even partially liable for DuPont's PFOA claims, the costs could run into the billions of dollars, on top of the debt and other liabilities with which Chemours is already saddled. That would put a huge dent in Chemours' balance sheet and almost certainly cause the stock to drop. Even with its recent gains, Chemours is a risky bet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.